NCT04897763View on ClinicalTrials.gov

Assessment of safEty, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled giRenTuximab (89Zr-Girentuximab) in patIents With Non-musclE-iNvasive Bladder CancEr (NMIBC)

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

August 24, 2022

Study Completion Date

September 26, 2022

Conditions
Bladder Cancer
Interventions
DRUG

89Zr-TLX250 PET/CT

Pretherapeutic 89Zr-TLX250 PET/CT

Trial Locations (1)

44805

Institut de cancerologie de l'Ouest, Saint-Herblain

Sponsors

Collaborators (1)

ATONCO
All Listed Sponsors
collaborator

ATONCO

UNKNOWN

lead

Institut Cancerologie de l'Ouest

OTHER

NCT04897763 - Assessment of safEty, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled giRenTuximab (89Zr-Girentuximab) in patIents With Non-musclE-iNvasive Bladder CancEr (NMIBC) | Biotech Hunter | Biotech Hunter